专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2011006278A1 SPHERICAL MAGNESIUM HALIDE ADDUCT, CATALYST COMPONENT AND CATALYST FOR OLEFIN POLYMERIZATION PREPARED THEREFROM 审中-公开
标题翻译：球形镁盐助剂，其制备的烯烃聚合催化剂组分和催化剂
公开(公告)号：WO2011006278A1
公开(公告)日：2011-01-20
申请号：PCT/CN2009000796
申请日：2009-07-15
申请人： CHINA PETROLEUM & CHEMICAL , BEIJING RES INST CHEM IND , XIA XIANZHI , LIU YUEXIANG , ZHANG JIGUI , WANG XINSHENG , GAO PING , QIAO SUZHEN , YIN MAOPING , LI WEILI , ZHANG TIANYI , PENG RENQI , CHEN YING , ZHANG ZHIHUI
发明人： XIA XIANZHI , LIU YUEXIANG , ZHANG JIGUI , WANG XINSHENG , GAO PING , QIAO SUZHEN , YIN MAOPING , LI WEILI , ZHANG TIANYI , PENG RENQI , CHEN YING , ZHANG ZHIHUI
IPC分类号： C08F4/02 , C07F3/02 , C08F4/654 , C08F10/00 , C08F10/06
CPC分类号： C08F110/06 , C07F3/003 , C08F10/00 , C08F4/6543 , C08F4/651 , C08F2500/12 , C08F2500/15 , C08F2500/24
摘要： A magnesium halide adduct represented by the formula (I): MgX2 mROH nE pH2O, in which X is chlorine, bromine, a C1-C12 alkoxy, a C3-C10 cycloalkoxy or a C6-C10 aryloxy, with the proviso that at least one X is chlorine or bromine; R is a C1-C12 alkyl, a C3-C10 cycloalkyl or a C6-C10 aryl; E is an o-alkoxybenzoate compound represented by the formula (II): in which R1 and R2 groups are independently a C1-C12 linear or branched alkyl, a C3-C10 cycloalkyl, a C6-C10aryl, a C7-C10 alkaryl or an C7-C10 aralkyl, the R1 and R2 groups are identical to or different from the R group; m is in a range of from 1.0 to 5.0; n is in a range of from O.OOlto 0.5; and p is in a range of from 0 to 0.8, is disclosed. A catalyst component useful in olefin polymerization, which comprises a reaction product of (1) the magnesium halide adduct, (2) a titanium compound, and optionally (3) an electron donor compound, is also disclosed.
摘要翻译：由式（I）表示的卤化镁加合物：MgX 2 mROH nE pH 2 O，其中X是氯，溴，C 1 -C 12烷氧基，C 3 -C 10环烷氧基或C 6 -C 10芳氧基，条件是至少一个 X是氯或溴; R是C1-C12烷基，C3-C10环烷基或C6-C10芳基; E是由式（II）表示的邻烷氧基苯甲酸酯化合物：其中R 1和R 2基团独立地为C 1 -C 12直链或支链烷基，C 3 -C 10环烷基，C 6 -C 10芳基，C 7 -C 10烷芳基或 C7-C10芳烷基，R1和R2基团与R基团相同或不同; m为1.0〜5.0的范围; n在0.001至0.5的范围内; 并且p在0至0.8的范围内。还公开了可用于烯烃聚合的催化剂组分，其包含（1）卤化镁加合物，（2）钛化合物和任选的（3）电子给体化合物的反应产物。

2. 发明申请

WO2004010972A3 PELLICLE-RESISTANT GELATIN CAPSULE 审中-公开
标题翻译：耐胶质明胶胶囊
公开(公告)号：WO2004010972A3
公开(公告)日：2004-07-29
申请号：PCT/US0324042
申请日：2003-07-31
申请人： PHARMACIA CORP , GAO PING
发明人： GAO PING
IPC分类号： A61K9/107 , A61K9/48 , A61K9/66 , A61K31/132 , A61K31/133 , A61K31/18 , A61K31/197 , A61K31/365 , A61K31/415 , A61K31/4164 , A61K31/42 , A61K31/495 , A61K31/50 , A61K31/635 , A61K45/00 , A61K47/02 , A61K47/04 , A61K47/10 , A61K47/12 , A61K47/14 , A61K47/16 , A61K47/18 , A61K47/20 , A61K47/22 , A61K47/34 , A61K47/36 , A61K47/42 , A61P1/04 , A61P1/16 , A61P3/10 , A61P5/14 , A61P9/00 , A61P9/10 , A61P11/00 , A61P11/06 , A61P15/00 , A61P15/06 , A61P17/00 , A61P17/02 , A61P17/06 , A61P17/10 , A61P17/16 , A61P19/02 , A61P21/00 , A61P21/04 , A61P25/04 , A61P25/06 , A61P25/28 , A61P25/32 , A61P27/02 , A61P29/00 , A61P31/12 , A61P31/18 , A61P33/00 , A61P35/00 , A61P43/00
CPC分类号： A61K9/485 , A61K9/1075 , A61K9/4825 , A61K9/4858 , A61K9/4866 , A61K31/18 , A61K31/635
摘要： The present invention relates to compositions suitable for use in preparing gelatin capsules, to gelatin capsules exhibiting reduced cross-linking, and to methods of preparing such gelatin capsules.
摘要翻译：本发明涉及适用于制备明胶胶囊的组合物，显示交联减少的明胶胶囊，以及制备这种明胶胶囊的方法。

3. 发明申请

WO02064132A2 CHEMOTHERAPEUTIC MICROEMULSION COMPOSITIONS OF PACLITAXEL WITH IMPROVED ORAL BIOAVAILABILITY 审中-公开
标题翻译：具有改善口腔生物利用度的PACLITAXEL的化学微乳剂组合物
公开(公告)号：WO02064132A2
公开(公告)日：2002-08-22
申请号：PCT/US0200497
申请日：2002-01-14
申请人： UPJOHN CO , GAO PING , MOROZOWICH WALTER
发明人： GAO PING , MOROZOWICH WALTER
IPC分类号： A61K9/48 , A61K31/00 , A61K31/122 , A61K31/138 , A61K31/277 , A61K31/337 , A61K31/352 , A61K31/365 , A61K31/415 , A61K31/42 , A61K31/444 , A61K31/49 , A61K31/50 , A61K31/52 , A61K31/5415 , A61K38/00 , A61K45/00 , A61K47/10 , A61K47/14 , A61K47/16 , A61K47/22 , A61K47/32 , A61K47/34 , A61K47/36 , A61K47/38 , A61P35/00 , A61P43/00 , A61K31/335 , A61K9/107 , A61K47/44
CPC分类号： B82Y5/00 , A61K9/4816 , A61K9/4858 , A61K9/4866 , A61K31/00 , A61K31/122 , A61K31/337 , A61K31/352 , A61K31/365 , A61K31/415 , A61K31/42 , A61K31/444 , A61K31/50 , A61K31/52 , A61K2300/00
摘要： Pharmaceutical compositions suitable for oral administration comprising paclitaxel, a solvent, a surfactant, a substituted cellulosic polymer, and optionally but preferably a P-glycoprotein inhibitor. The composition may further comprise a diglyceride or mixture of diglyceride and monoglyceride. The composition generates a supersaturated paclitaxel microemulsion upon contact with water resulting in improved oral bioavailability of paclitaxel.
摘要翻译：适用于口服给药的药物组合物包括紫杉醇，溶剂，表面活性剂，取代纤维素聚合物，以及任选但优选P-糖蛋白抑制剂。组合物还可以包含甘油二酯或甘油二酯和甘油单酯的混合物。组合物在与水接触时产生过饱和紫杉醇微乳液，导致紫杉醇的口服生物利用度得到改善。

4. 发明申请

WO2005046455A2 METHODS FOR IDENTIFYING OR MONITORING A PATIENT WITH INCREASED RISK OF CARDIOVASCULAR CALCIFICATION 审中-公开
标题翻译：识别或监测具有增加心脏血管计算风险的患者的方法
公开(公告)号：WO2005046455A2
公开(公告)日：2005-05-26
申请号：PCT/US2004037797
申请日：2004-11-12
申请人： GAO PING
发明人： GAO PING
IPC分类号： A61B20060101 , G01N33/53 , G01N33/537 , G01N33/543 , G01N33/68 , G01N33/84 , A61B
CPC分类号： G01N33/6893 , G01N33/84 , G01N2800/32 , G01N2800/52
摘要： The present invention includes novel methods of using a calcification risk index (CRI) for identifying or monitoring a patient with increased risk of cardiovascular calcification and/or mortality, or monitoring an effect of therapeutic treatment for a patient having cardiovascular calcification or with increased risk of cardiovascular calcification. The methods may include determining an alpha-2 HS glycoprotein level or circulating calcification inhibitory capacity in a biological sample, and comparing the level to at least one of the parameters selected from a calcium level, a phosphate level and a calcium x phosphate product level, or the combination of these values. The present invention may allow one able to identify or monitor a patient having increased risk of cardiovascular calcification and/or predicting mortality, or to monitor an effect of treatment for a patient having an increased risk of cardiovascular calcification or a patient who already has cardiovascular calcification.
摘要翻译：本发明包括使用钙化风险指数（CRI）来鉴定或监测具有心血管钙化和/或死亡风险增加的患者的新方法，或监测对具有心血管钙化或风险增加的患者的治疗性治疗的效果心血管钙化。所述方法可以包括确定生物样品中的α-2 HS糖蛋白水平或循环钙化抑制能力，并将该水平与选自钙水平，磷酸盐水平和磷酸钙产物水平的至少一个参数进行比较，或这些值的组合。本发明可以允许能够识别或监测具有增加的心血管钙化风险和/或预测死亡率的患者，或监测具有升高的心血管钙化风险的患者或已经具有心血管钙化的患者的治疗效果。

5. 发明申请

WO2004022032A3 PHARMACEUTICAL DOSAGE FORM COMPRISING A SULFITE COMPOUND 审中-公开
标题翻译：包含硫化合物的药物剂型
公开(公告)号：WO2004022032A3
公开(公告)日：2004-08-12
申请号：PCT/US0324044
申请日：2003-07-31
申请人： PHARMACIA CORP , GAO PING , BAUER JULIANE M , EWING GARY , SPERRY DAVID
发明人： GAO PING , BAUER JULIANE M , EWING GARY , SPERRY DAVID
IPC分类号： A61K9/107 , A61K9/48 , A61K9/66 , A61K31/132 , A61K31/133 , A61K31/18 , A61K31/197 , A61K31/365 , A61K31/415 , A61K31/4164 , A61K31/42 , A61K31/495 , A61K31/50 , A61K31/635 , A61K45/00 , A61K47/02 , A61K47/04 , A61K47/10 , A61K47/12 , A61K47/14 , A61K47/16 , A61K47/18 , A61K47/20 , A61K47/22 , A61K47/34 , A61K47/36 , A61K47/42 , A61P1/04 , A61P1/16 , A61P3/10 , A61P5/14 , A61P9/00 , A61P9/10 , A61P11/00 , A61P11/06 , A61P15/00 , A61P15/06 , A61P17/00 , A61P17/02 , A61P17/06 , A61P17/10 , A61P17/16 , A61P19/02 , A61P21/00 , A61P21/04 , A61P25/04 , A61P25/06 , A61P25/28 , A61P25/32 , A61P27/02 , A61P29/00 , A61P31/12 , A61P31/18 , A61P33/00 , A61P35/00 , A61P43/00
CPC分类号： A61K9/485 , A61K9/1075 , A61K9/4825 , A61K9/4858 , A61K9/4866 , A61K31/18 , A61K31/635
摘要： The present invention provides a pharmaceutical dosage form comprising a fill material sealed in a gelatin capsule; the fill material comprises (a) a selective COX-2 inhibitory drug of low water solubility, and (b) a sulfite compound in an amount sufficient to inhibit cross-linking of gelatin in said gelatin capsule upon storage of the dosage form in a closed container maintained at 40 DEG C and 75% relative humidity for a period of 6 months.
摘要翻译：本发明提供一种药物剂型，其包含密封在明胶胶囊中的填充材料; 填充材料包含（a）低水溶性的选择性COX-2抑制药物，和（b）足够的量的亚硫酸盐化合物，其量足以抑制所述明胶胶囊中明胶的交联，容器保持在40℃和75％相对湿度下，持续6个月。

6. 发明申请

WO02102376A8 ORALLY DELIVERABLE PHARMACEUTICAL COMPOSITION COMPRISING AN ACTIVE COMPOUND HAVING AN AMINOSULFONYL GROUP (cox-2 INHIBITOR), A POLYETHYLENE GLYCOL AND A FREE-RADICAL SCAVENGING ANTIOXIDANT 审中-公开
标题翻译：包含具有氨基磺酸基团（cox-2抑制剂）的活性化合物，聚乙烯甘油和免费放射性抗氧化剂的可交付的药物组合物
公开(公告)号：WO02102376A8
公开(公告)日：2003-04-24
申请号：PCT/US0211690
申请日：2002-04-12
申请人： PHARMACIA CORP , GAO PING , HUANG TIEHUA , ROBINS RUSSELL H , BAUER JULIANE M , GUIDO JANE E , BRUGGER ANDREW M , KARIM AZIZ , HASSAN FRED , FORBES JAMES C
发明人： GAO PING , HUANG TIEHUA , ROBINS RUSSELL H , BAUER JULIANE M , GUIDO JANE E , BRUGGER ANDREW M , KARIM AZIZ , HASSAN FRED , FORBES JAMES C
IPC分类号： A61K9/08 , A61K9/48 , A61K31/415 , A61K31/42 , A61K31/522 , A61K31/635 , A61K45/00 , A61K45/06 , A61K47/02 , A61K47/04 , A61K47/10 , A61K47/12 , A61K47/18 , A61K47/22 , A61K47/34 , A61K47/38 , A61K47/48 , A61P25/06 , A61P29/00 , A61P43/00 , C07D231/12 , C07D261/08 , C07D413/12
CPC分类号： C07D231/12 , A61K9/0019 , A61K9/4858 , A61K9/4866 , A61K31/415 , A61K31/42 , A61K31/635 , A61K47/02 , A61K47/12 , A61K47/22 , A61K47/38 , A61K47/60 , C07D261/08 , C07D413/12
摘要： An orally deliverable pharmaceutical composition is provided comprising an aminosulfonyl-comprising drug, for example a selective cyclooxygenase-2 inhibitory drug such as celecoxib, and a solvent liquid comprising a polyethylene glycol and one or more free radical-scavenging antioxidants. At least a substantial part of the drug is in dissolved form in the solvent liquid. The composition has rapid-onset properties and is useful in treatment of cyclooxygenase-2 mediated conditions and disorders.
摘要翻译：提供了包含含氨基磺酰基的药物，例如选择性环加氧酶-2抑制药物如塞来昔布的口服递送药物组合物，以及包含聚乙二醇和一种或多种自由基清除抗氧化剂的溶剂液体。至少大部分药物溶解在溶剂液体中。该组合物具有快速发作性质，可用于治疗环氧合酶-2介导的病症和病症。

7. 发明申请

WO0190103A3 3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AND THEIR USE AS PROTEIN KINASE MODULATORS 审中-公开
标题翻译： 3-（吡咯-2-基甲基）-2-吲哚啉酮衍生物及其作为蛋白激酶调节剂的用途
公开(公告)号：WO0190103A3
公开(公告)日：2002-07-18
申请号：PCT/US0116741
申请日：2001-05-24
申请人： SUGEN INC , UPJOHN CO , MOON MALCOLM WILSON , MOROZOWICH WALTER , GAO PING , KOENIG MARCEL
发明人： MOON MALCOLM WILSON , MOROZOWICH WALTER , GAO PING , KOENIG MARCEL
IPC分类号： C07D401/06 , A61K31/404 , A61K31/4045 , A61K31/4439 , A61K31/496 , A61K31/661 , A61P1/00 , A61P1/16 , A61P3/00 , A61P3/10 , A61P7/02 , A61P9/00 , A61P9/08 , A61P9/10 , A61P11/00 , A61P13/12 , A61P17/00 , A61P17/02 , A61P17/06 , A61P19/02 , A61P19/04 , A61P25/00 , A61P25/28 , A61P29/00 , A61P31/00 , A61P31/04 , A61P35/00 , A61P37/00 , A61P37/06 , A61P43/00 , C07D401/14 , C07D403/06 , C07D403/14 , C07F9/572 , C07F9/6558 , C07F9/09
CPC分类号： C07D403/06 , C07D403/14 , C07F9/5728 , C07F9/65583
摘要： The present invention is directed to prodrugs of certain 3-(pyrrol-2-yl-methylidene)-2-indolinone derivatives that modulate the activity of protein kinases ("PKs"). Pharmaceutical compositions comprising these compounds, methods of treating diseases related to abnormal PK activity utilizing pharmaceutical compositions comprising these compounds and methods of preparing them are also disclosed.
摘要翻译：本发明涉及调节蛋白激酶（“PK”）活性的某些3-（吡咯-2-基 - 亚甲基）-2-二氢吲哚酮衍生物的前药。还公开了包含这些化合物的药物组合物，使用包含这些化合物的药物组合物治疗与异常PK活性有关的疾病的方法及其制备方法。

8. 发明申请

WO2010033871A3 COMPOSITIONS AND METHODS TARGETING GLUTAMINASE 审中-公开
标题翻译：组合物和靶向谷氨酰胺酶的方法
公开(公告)号：WO2010033871A3
公开(公告)日：2010-07-15
申请号：PCT/US2009057583
申请日：2009-09-18
申请人： UNIV JOHNS HOPKINS , DANG CHI V , GAO PING
发明人： DANG CHI V , GAO PING
IPC分类号： A61K48/00 , A61P35/00 , C12N15/113 , C12N15/63 , C12Q1/68
CPC分类号： C12N15/1137 , C12N2310/11 , C12N2310/14 , C12N2310/141 , C12Y305/01002
摘要： The invention provides compositions and methods featuring nucleic acid molecules that target glutaminase. The methods of the invention involve administering a nucleic acid to a cell of a subject diagnosed as having a neoplasia in order to inhibit the expression of glutaminase.
摘要翻译：本发明提供了靶向谷氨酰胺酶的核酸分子的组合物和方法。本发明的方法包括将核酸施用于被诊断患有瘤形成的受试者的细胞以抑制谷氨酰胺酶的表达。

9. 发明申请

WO2006079923A3 FORM IV CRYSTALLINE CELECOXIB 审中-公开
标题翻译： FORM IV水晶CELECOXIB
公开(公告)号：WO2006079923A3
公开(公告)日：2006-12-07
申请号：PCT/IB2006000190
申请日：2006-01-19
申请人： PHARMACIA & UPJOHN CO LLC , HAWLEY MICHAEL , LU GUANG WEI , GEIGER BRENDA MAE , SMITH MARK ALAN , GAO PING , HAGEMAN MICHAEL JOHN , EWING GARY DOUGLAS
发明人： HAWLEY MICHAEL , LU GUANG WEI , GEIGER BRENDA MAE , SMITH MARK ALAN , GAO PING , HAGEMAN MICHAEL JOHN , EWING GARY DOUGLAS
IPC分类号： C07D231/12 , A61K31/415
CPC分类号： C07D231/12
摘要： A novel crystalline form of celecoxib (4-[5-(4-methylphenyl)-3-(trifluoromethyl)1H-pyrazol-1-yl] benzenesulfonamide), methods for its preparation, and pharmaceutical compositions comprising the same are described.
摘要翻译：描述了塞来昔布（4- [5-（4-甲基苯基）-3-（三氟甲基）-1H-吡唑-1-基]苯磺酰胺的新型结晶形式，其制备方法和包含其的药物组合物。

10. 发明申请

WO2004010973A2 PHARMACEUTICAL DOSAGE FORM CAPABLE OF MAINTAINING STABLE DISSOLUTION PROFILE UPON STORAGE 审中-公开
标题翻译：药物剂型可保存稳定的溶出曲线
公开(公告)号：WO2004010973A2
公开(公告)日：2004-02-05
申请号：PCT/US0324043
申请日：2003-07-31
申请人： PHARMACIA CORP , GAO PING , BAUER JULIANE M , HE XIAORONG
发明人： GAO PING , BAUER JULIANE M , HE XIAORONG
IPC分类号： A61K9/107 , A61K9/48 , A61K9/66 , A61K31/132 , A61K31/133 , A61K31/18 , A61K31/197 , A61K31/365 , A61K31/415 , A61K31/4164 , A61K31/42 , A61K31/495 , A61K31/50 , A61K31/635 , A61K45/00 , A61K47/02 , A61K47/04 , A61K47/10 , A61K47/12 , A61K47/14 , A61K47/16 , A61K47/18 , A61K47/20 , A61K47/22 , A61K47/34 , A61K47/36 , A61K47/42 , A61P1/04 , A61P1/16 , A61P3/10 , A61P5/14 , A61P9/00 , A61P9/10 , A61P11/00 , A61P11/06 , A61P15/00 , A61P15/06 , A61P17/00 , A61P17/02 , A61P17/06 , A61P17/10 , A61P17/16 , A61P19/02 , A61P21/00 , A61P21/04 , A61P25/04 , A61P25/06 , A61P25/28 , A61P25/32 , A61P27/02 , A61P29/00 , A61P31/12 , A61P31/18 , A61P33/00 , A61P35/00 , A61P43/00 , A61K9/00
CPC分类号： A61K9/485 , A61K9/1075 , A61K9/4825 , A61K9/4858 , A61K9/4866 , A61K31/18 , A61K31/635
摘要： The present invention provides a pharmaceutical dosage form comprising a fill material sealed in a gelatin capsule; the fill material comprises (a) a selective COX-2 inhibitory drug of low water solubility, and (b) a primary or secondary amine compound in an amount sufficient to inhibit cross-linking of gelatin in said gelatin capsule upon storage of the dosage form in a closed container maintained at 40 °C and 75 % relative humidity for a period of 6 months.
摘要翻译：本发明提供了包含密封在明胶胶囊中的填充材料的药物剂型; 所述填充材料包含（a）低水溶性的选择性COX-2抑制药，和（b）伯或仲胺化合物，其量足以在储存所述剂型时抑制所述明胶胶囊中明胶的交联在保持在40℃和75％相对湿度的封闭容器中保存6个月。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式